A Plea for Economically Sustainable Evidence-based Guidelines

Alberto Martini(The University of Texas MD Anderson Cancer Center), Bernard Malavaud(Institut universitaire du cancer de Toulouse Oncopole), María J. Ribal(Hospital Clínic de Barcelona), Nicolas Mottet(Centre Hospitalier Universitaire de Saint-Étienne), Francesco Montorsi(Vita-Salute San Raffaele University), Andrea Necchi(Vita-Salute San Raffaele University)
European Urology
August 20, 2022
10.1016/j.eururo.2022.08.001
Cited by 11

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
|European Urology|2020|2.2k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k